STOCK TITAN
  1. Home
  2. Sec-filings
  3. RCKT
  4. [Form 4] Rocket Pharmaceuticals, Inc. Insider Trading Activity

RCKT Insider Sale: John Militello Sells 1,060 Shares for Tax Withholding

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

John Militello, Vice President of Finance, Treasurer and Principal Accounting Officer at Rocket Pharmaceuticals, Inc. (RCKT), reported two sales of common stock tied to RSU vesting. On 08/18/2025 he sold 699 shares at $3.065, leaving 56,285 shares beneficially owned. On 08/19/2025 he sold 361 shares at $2.996, leaving 55,924 shares owned. The filing states these shares were sold to pay tax withholding obligations related to Restricted Stock Units that convert one-for-one to common stock. The Form 4 was signed by an attorney-in-fact on 08/20/2025.

Positive

  • Transparent disclosure of dates, share amounts and prices for the sales
  • Reason for sale provided (tax withholding related to RSU vesting), reducing potential misinterpretation
  • Timely filing with signature provided by attorney-in-fact

Negative

  • Insider sale of 1,060 shares reduces the reporting person's beneficial ownership from 56,285 to 55,924 shares
  • Sales occurred at low prices (~$3.00), which could be viewed negatively by some investors despite being for tax withholding

Insights

TL;DR: Insider sales were executed to satisfy tax withholding on RSU vesting; transaction sizes are small relative to total shares outstanding.

The reported transactions are routine tax withholdings following RSU vesting rather than open-market disposals for other purposes. The total sold was 1,060 shares across two days at prices near $3.00. Such sales typically have limited informational content about company prospects but reduce the insider's post-transaction holdings modestly from 56,285 to 55,924 shares.

TL;DR: Filing shows timely disclosure and describes the sales as tax-withholding related, consistent with standard RSU practices.

The Form 4 discloses the reporting persons role and the reason for the sales (tax withholding for RSU vesting), which aligns with common disclosure practices. The document is signed by an attorney-in-fact, indicating proper execution. The transactions appear administrative in nature and the filing provides clear quantities, dates and prices for investor transparency.

Insider Militello John
Role See Remarks
Sold 1,060 shs ($3K)
Type Security Shares Price Value
Sale Common Stock 361 $2.996 $1K
Sale Common Stock 699 $3.065 $2K
Holdings After Transaction: Common Stock — 55,924 shares (Direct)
Footnotes (2)
  1. F1. Holdings include Restricted Stock Units ("RSUs") that convert to common stock on a one-for-one basis.
  2. F2. The shares of common stock were sold by the Reporting Person in order to pay tax withholding obligations in connection with the vesting of RSUs.

FAQ

What did John Militello report on Form 4 for RCKT?
He reported selling 699 shares on 08/18/2025 at $3.065 and 361 shares on 08/19/2025 at $2.996 to satisfy tax withholding on RSU vesting.

Why were the shares sold according to the filing?
The filing states the shares were sold to pay tax withholding obligations in connection with Restricted Stock Units that convert one-for-one to common stock.

How many shares does Militello beneficially own after the reported transactions?
After the sales reported, his beneficial ownership is listed as 55,924 shares following the 08/19/2025 sale.

Who signed the Form 4 and when?
The form was signed by Martin Wilson, as attorney-in-fact for John Militello on 08/20/2025.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Militello John
(Last) (First) (Middle)
C/O ROCKET PHARMACEUTICALS, INC.
9 CEDARBROOK DRIVE
(Street)
CRANBURY NJ 08512
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
ROCKET PHARMACEUTICALS, INC. [ RCKT ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
See Remarks
3. Date of Earliest Transaction (Month/Day/Year)
08/18/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock(1) 08/18/2025 S(2) 699 D $3.065 56,285 D
Common Stock(1) 08/19/2025 S(2) 361 D $2.996 55,924 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. Holdings include Restricted Stock Units ("RSUs") that convert to common stock on a one-for-one basis.
2. The shares of common stock were sold by the Reporting Person in order to pay tax withholding obligations in connection with the vesting of RSUs.
Remarks:
Vice President of Finance, Treasurer, Principal Accounting Officer
/s/ Martin Wilson, as attorney-in-fact for John Militello 08/20/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR